Fosravuconazole is a triazole antifungal compound developed as a prodrug of ravuconazole. It is designed to provide systemic antifungal activity following conversion to its active metabolite. Fosravuconazole has been investigated and developed for the treatment of fungal infections, particularly onychomycosis. Its chemical name is (2R,3S)-2-(2,4-difluorophenyl)-3-(1H-1,2,4-triazol-1-yl)-1-(1H-1,2,4-triazol-1-ylmethyl)-3-(2,4,5-trifluorophenyl)butan-2-ol.
Fosravuconazole is a prodrug of ravuconazole. After administration, it is converted to ravuconazole, which inhibits fungal lanosterol 14α-demethylase (CYP51), interfering with ergosterol biosynthesis and fungal cell membrane formation.
